TNF-alpha Agonists

Cat.No.	Product Name	Information	Product Use Citations
S7942	Bioymifi	Bioymifi, a small-molecule death receptor 5 (DR5) agonist, binds to the extracellular domain(ECD) of DR5 with a Kd of 1.2 μM but showed little binding affinity to the DR4 ECD. It induces DR5 clustering and aggregation, leading to apoptosis.	Cell Death Dis, 2024, 15(1):27 Front Immunol, 2020, 11:1345
S8133	Resiquimod (R-848)	Resiquimod (R-848, S28463) is an immune response modifier that acts as a potent TLR 7/TLR 8 agonist, inducing the upregulation of cytokines such as TNF-α, IL-6 and IFN-α. This compound reduces hepatitis C virus (HCV) infection. Phase 2.	Nature, 2025, 644(8078):1058-1068 J Virol, 2025, e0128025. Int J Nanomedicine, 2024, 19:3589-3605
E2630	SKF-86002	SKF-86002 is an orally active p38 MAPK inhibitor, inhibits lipopolysaccharide (LPS)-stimulate human monocyte IL-1 and TNF-α production with IC50 of 1 μM, also inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid.

Cat.No.

Product Name

Information

Product Use Citations

Product Validations

S7942

Bioymifi

Bioymifi, a small-molecule death receptor 5 (DR5) agonist, binds to the extracellular domain(ECD) of DR5 with a Kd of 1.2 μM but showed little binding affinity to the DR4 ECD. It induces DR5 clustering and aggregation, leading to apoptosis.

Cell Death Dis, 2024, 15(1):27

Front Immunol, 2020, 11:1345

S8133

Resiquimod (R-848)

Resiquimod (R-848, S28463) is an immune response modifier that acts as a potent TLR 7/TLR 8 agonist, inducing the upregulation of cytokines such as TNF-α, IL-6 and IFN-α. This compound reduces hepatitis C virus (HCV) infection. Phase 2.

Nature, 2025, 644(8078):1058-1068

J Virol, 2025, e0128025.

Int J Nanomedicine, 2024, 19:3589-3605

E2630

SKF-86002

SKF-86002 is an orally active p38 MAPK inhibitor, inhibits lipopolysaccharide (LPS)-stimulate human monocyte IL-1 and TNF-α production with IC50 of 1 μM, also inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid.